AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06249997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leniolisib
Description: The doses selected range from 40 to 70 mg BID (based on body weight, resulting in total daily doses ranging from 80 to 140 mg a day for 12 weeks in Part I and 1 year in Part II, or until marketing approval in Japan, whichever is longer.
Study NCT06509399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care package
Description: Before the patients in the application group started to be observed, the nurses working in the clinic were trained about the risk assessment, skin assessment, incontinence management, nutrition assessment, positioning, support surfaces and injuries caused by the devices in the BP content to be used in the prevention of IU. After the trainings given to the nurses were completed, care was given to the patients in the practice group in accordance with BP. In addition, patient information was collected from patient information files, nurse observation forms and hospital automation system. In the evaluation step, full compliance with the 7 compliance steps specified in the BP was sought. If any one of these parameters was incomplete, the others were considered as incomplete.~The patients in the control group were followed up for 30 days until the determined number of patients was reached and their data were collected.
Study NCT04239131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin prick test
Description: a Skin prick test is planned in all patients
Study NCT04917614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: Transcutaneous Electrical Acupoint Stimulation
Study NCT05231343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual Mini-fragment Plating
Description: Patients randomized to dual mini-fragment plating will undergo clavicle fixation using any configuration of 2.0-mm, 2.4-mm and 2.7-mm limited contact dynamic compression (LC-DCP), locking compression (LCP) or reconstruction plates (i.e., 2.4-mm superior and 2.7-mm anteroinferior). One of the two plates used must be a LC-DCP or LCP plate. Surgeons will contour the mini-fragment plate intraoperatively to fit each patient's anatomy.
Study NCT05231343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Precontoured Plating
Description: Patients randomized to a single plate construct will undergo fixation using an anatomically precontoured (superior or anterior-inferior) clavicle plate.
Study NCT04970121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine, tablets, 20mg as starting dose and up to 60mg as maximum dose, once daily.~Taxanes is used according to manual instruction and patient condition.
Study NCT06201039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Lidocaine Hydrochloride
Description: Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 24 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI block will start immediately at a speed of 4ml/h containing 0.5% lidocaine hydrochloride + 1:400000 adrenaline.
Study NCT06201039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 72 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI placebo will start immediately at a speed of 4ml/h containing 0.9% normal saline + 1:400000 adrenaline.
Study NCT06422000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline 30 mg/kg given over 6 hours daily
Study NCT06422000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Formula
Description: probiotics sachets supplementation, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement .
Study NCT05400577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
Description: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
Study NCT03429777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HearMe Smartphone Application
Description: The HearMe smartphone application is a digits-in-noise test that can be used to digitally quantify speech reception thresholds.
Study NCT03429777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HearMe Smartphone Application
Description: The HearMe smartphone application is a digits-in-noise test that can be used to digitally quantify speech reception thresholds.
Study NCT05549492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25%-NaCl 0.9% Injectable Solution
Description: The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.
Study NCT06066411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Ball
Description: The massage ball application will be applied to the patients by the researcher for 20 minutes every day for 3 days.
Study NCT04707664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days.
Study NCT04707664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.
Study NCT05689242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: intravenous dexmedetomidine for group I and nalubphine for group II in colposcopy
Study NCT05135676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blinded CGM
Description: A masked CGM sensor will be worn
Study NCT05135676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time CGM
Description: An unmasked CGM sensor will worn
Study NCT05337098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Nutritive Sweetener Intake and impact on glucose homeostasis
Description: Provision of either aspartame, sucralose, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
Study NCT05646030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TAP-II
Description: The TAP-II device will be compared to lancet capillary sampling and the venipuncture
Study NCT05646030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lancet capillary sampling
Description: The lancet capillary sampling will be compared to TAP device and the venipuncture
Study NCT05646030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Venipuncture
Description: The venipuncture will be compared to TAP device and the lancet capillary sampling
Study NCT06574568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKST02
Description: BCMA-CD3 bispecific antibody
Study NCT05617807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanoscopic partial meniscectomy
Description: Patients will have a partial meniscectomy performed using the arthrex nanoscope and it will be compared to partial meniscectomy performed using standard arthroscopic equipment
Study NCT05617807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Partial Meniscectomy
Description: Patients will have partial meniscectomy performed using standard arthroscopic equipment
Study NCT05853718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide Tablets
Description: Take 25mg TAF daily from week 28-32 of gestation until delivery
Study NCT05745545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine
Description: One dose was administered by intramuscular injection, 100μg，1.0ml/dose
Study NCT05745545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: One dose was administered by intramuscular injection, 0.5ml/vial
Study NCT05255094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered AK102 by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study NCT05255094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered AK102 by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study NCT05255094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered placebo by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study NCT05255094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered placebo by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study NCT06232967 — intervention group
Intervention type: PROCEDURE
Intervention: Primary tumor resection or not
Description: For patients with non-small-cell lung cancer (NSCLC) and dry pleural dissemination, surgical decisions to perform exploratory thoracotomy only or primary tumor resection with wedge resection, segmentectomy, or lobectomy were based on surgeon experience and patient preference.
Study NCT04878120 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard HCL System
Description: Standard HCL system (USS Virginia)
Study NCT04878120 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HCL System with Smart Bolus Calculator
Description: HCL system (USS Virginia) with smart bolus calculator informed by insulin sensitivity
Study NCT05438238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oncomfort
Description: Virtual Reality
Study NCT05337098 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-Nutritive Sweetener Intake and impact on glucose homeostasis
Description: Provision of either aspartame, sucralose, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
Study NCT06055504 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Strategy
Description: ICDs will be implanted in all patients according to current recommendations
Study NCT06055504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized precision ICD implantation Strategy based in genetic findings and CMR results
Description: Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a DCM-causing pathogenic or likely pathogenic genetic variants or LGE in CMR. Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.
Study NCT04548284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Periorbital injection of glucocorticoid. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
Study NCT06446687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant with sinus lifting.
Description: Surgery will be performed under local infiltration anaesthesia. Flap will be done. For maxillary sinus lifting by using Crestal approach with Membrane Control Technique by Wang (Wang, 2017) will be employed. After reflecting on the flap, Magic Split will be used to confirm bone quality clinically. This will be followed by site preparation using Magic Marking Drill. Bone drilling will then be performed by Magic Drill shorter by 2 mm from the sinus floor. This will be followed by sinus lifting by using Magic Sinus Lifter (MSL). The 3mm space of the apex of the Sinus Lifter instrument enables direct control of the bone-block and consequently the membrane, which is connected to the bone-block. the fixture will be installed in the conventional method. Then cover the fixture with the cover screw. The flap will be sutured. An immediate CBCT will be requested to ensure the implant is in its proper position.
Study NCT04853446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg
Description: Two identically appearing, opaque capsules will be administered: one capsule containing 12 mg of dexamethasone and one capsule containing placebo.
Study NCT04853446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two identically appearing, opaque capsules will be administered: two capsules containing placebo.
Study NCT06128421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individual nutritional support
Description: Nutritional products and route（oral, parenteral）is possible to reach goals
Study NCT05709288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBM-H901
Description: Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of an hyper active human factor IX mutant(FIX Padua) transgene in liver. The dose of BBM-H901 is 5x10'12 vg/Kg.
Study NCT04853446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 24 mg
Description: Two identically appearing, opaque capsules will be administered: two capsules each containing 12mg dexamethasone.
Study NCT06563999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: 300 mg orally once a day, 28 days as one cycle.
Study NCT06563999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 300 mg orally once a day, 28 days as one cycle.
Study NCT06563999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Description: 400 mg orally once a day, 28 days as one cycle.
Study NCT06563999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Description: 100 mg orally twice daily, 28 days as one cycle.
Study NCT06563999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: 600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle.
Study NCT06563999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400 mg orally once a day, 28 days as one cycle.
Study NCT06563999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib+Trametinib
Description: Dabrafenib 150 mg orally twice daily, 28 days as one cycle. Trametinib 150 mg orally twice daily, 28 days as one cycle.
Study NCT06563999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecirasib
Description: 800 mg daily orally, 28 days as one cycle.
Study NCT06563999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: 225 mg daily orally, 28 days as one cycle.
Study NCT05594797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human BCMA Targeted T Cells Injection
Description: A single dose of predetermined level CAR-positive T cells will be infused.
Study NCT04770727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT workshop
Description: The CBT based intervention for adolescents will include psychoeducation on food allergy and anxiety and also focus on providing skills, knowledge and support.
Study NCT06346041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus injection(IDOV-SAFETM)
Description: Administered by intravenous injection as single agent.
Study NCT04753957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: micronized Progesterone
Description: 200mg micronized progesterone placed vaginally
Study NCT06329258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar
Description: Add on Enstilar
Study NCT06329258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: 6mg QD
Study NCT05525546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation
Description: One dose of the full-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The full-strength conjugate vaccine consists of 25 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
Study NCT05525546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation
Description: One dose of the half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The half-strength conjugate vaccine consists of 12.5 mcg of Salmonella Enteritidis, 12.5 mg of Salmonella Typhimurium, and 25 mcg of Salmonella Typhi Vi.
Study NCT05525546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation
Description: One dose of the dilutional half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The dilutional half-strength conjugate vaccine consists of 12.5 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
Study NCT05525546 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The placebo consists of sterile phosphate-buffered saline (PBS) solution containing polysorbate 80, and 2-phenoxyethanol preservative.
Study NCT05506969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rF1V vaccine and CpG 1018® adjuvant
Description: rF1V vaccine and CpG 1018® adjuvant
Study NCT05506969 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rF1V vaccine
Description: rF1V vaccine
Study NCT06305975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blunt fascial abdominal entry
Description: Blunt fascial entry technique description: a 5 mm incision is made in the umbilicus. Next, a curved Kelly forceps is used to open the fascia, and, if possible, the peritoneum. The Kelly forceps are then used to expand the opening to a 10 mm diameter. A 5 mm trocar is placed into the fascial hole and used to quickly insufflate the abdomen to 15 mm Hg. Once the abdomen is fully insufflated, a 10 mm trocar is placed using optical guidance.
Study NCT06305975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Veress needle abdominal entry
Description: Veress needle abdominal entry technique description: a 5 mm incision is made in the umbilicus. Next, a Veress needle is used to enter the peritoneal cavity and inflate the abdomen to 15 mm Hg. Once the abdomen is fully insufflated, a 10 mm trocar is placed using optical guidance.
Study NCT05903157 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Delivery of a health literacy flyer
Description: A health literacy flyer was delivered, by e-mail, in the first week of the intervention (the flyer contained its original source - the European Centre for Disease Prevention and Control). Beyond this, there was no further interaction with the group.~All primary and secondary outcome measures were assessed at baseline, one month later (in the middle of the intervention), post-intervention, and follow-up moments (3 and 6 months after the intervention).
Study NCT05903157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group: Weekly group sessions for weight management
Description: The eHealth intervention was designed based on: i) the Health Action Process Approach determinants, ii) the Health Belief Model constructs, and iii) behaviour change techniques (BCT, Taxonomy v1, by Michie et al., 2013) to implement healthy behaviours.~The intervention consists of 8 sessions (90 minutes, once a week). All group intervention sessions, through the Zoom platform, are led by the psychologist responsible for the study. Whatsapp groups were created, to share experiences, knowledge, doubts, fears...~All primary and secondary outcome measures were assessed at baseline, one month later (in the middle of the intervention), post-intervention, and in follow-up moments (3 and 6 months after the intervention).
Study NCT03735589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-type-1 Polarized Dendritic Cells
Description: Given ID
Study NCT03735589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Natural Killer Cell-like CTLs
Description: Given IP
Study NCT04860440 — intervention group
Intervention type: DEVICE
Intervention: GeneActiv wrist worn accelerometer
Description: Wrist worn device worn for 7 days
Study NCT00013247 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prostate Cancer Screening Education
Study NCT06316518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness group
Description: In the study, primigravidas will receive 8-module (8-week-long) trainings, each lasting approximately 45 minutes, 3 days a week.
Study NCT06316518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness group
Description: In the study, primigravidas will receive 8-module (8-week-long) trainings, each lasting approximately 45 minutes, 3 days a week.